Pharmacy and Therapeutics Committee Agenda for March 9, 2006

The Pharmacy & Therapeutics Committee will meet Thursday, March 09, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items:

1. Proposal: Identification of preferred drugs in the therapeutic class of Dihydropyridine Calcium Channel Blockers

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Adalat (nifedipine), Adalat CC (nifedipine CC), Afeditab CR (nifedipine CR), Cardene (nicardipine), Cardene SR (nicardipine SR), DynaCirc (isradipine), DynaCirc CR (isradipine CR), felodipine ER, isradipine, nicardipine HCl, Nifediac CC (nifedipine CC), Nifedical XL (nifedipine XL), nifedipine, nifedipine ER, nifedipine SA, Norvasc (amlodipine), Plendil (felodipine ER), Procardia (nifedipine), Procardia XL (nifedipine XL), Sular (nisoldipine)

 

2. Proposal: Identification of preferred drugs in the therapeutic class of Calcium Channel Blocker/ACE Receptor Inhibitor Combinations

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Lexxel (enalapril maleate/felodipine ER), Lotrel (benazepril HCL/amlodipine besylate), Tarka (trandolapril/verapamil HCL ER)

 

3. Proposal: Identification of preferred drugs in the therapeutic class of Beta Blockers.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: acebutolol, atenolol, atenolol/chlorthalidone, Betapace (sotalol), Betapace AF (sotalol AF), betaxolol, bisoprolol fumarate, bisoprolol fumarate/HCTZ, Blocadren (timolol), Cartrol (carteolol), Coreg (carvedilol), Corgard (nadolol), Corzide (nadolol/bendroflumethiazide), Inderal (propranolol), Inderal LA (propranolol LA), Inderide (propranolol/HCTZ), Inderide LA (propranolol LA/HCTZ), Innopran XL (propranolol XL), Kerlone (betaxolol), labetalol, Levatol (penbutolol), Lopressor (metoprolol tartrate), Lopressor HCT (metoprolol tartrate/HCTZ), metoprolol tartrate, metoprolol tartrate/HCTZ, nadolol, Normodyne (labetalol), pindolol, propranolol, propranolol/HCTZ), Sectral (acebutolol), Sorine (sotalol), sotalol, Tenoretic (atenolol/chlorthalidone), Tenormin (atenolol), Timolide (timolol maleate/HCTZ), timolol maleate, Toprol XL (metoprolol succinate XL), Trandate (labetalol), Zebeta (bisoprolol fumarate), Ziac (bisoprolol fumarate/HCTZ)

 

4. Proposal: Identification of preferred drugs in the therapeutic class of Bisphosphonates

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drugs Affected: Actonel (risedronate), Actonel with Calcium (risedronate with calcium carbonate), Boniva (ibandronate), Fosamax (alendronate), Fosamax Plus D (alendronate plus cholecalciferol)

Agenda
8:45 AM9:00 AMWelcome and Introductions
9:00 AM10:00 AMComments from Interested Parties*
10:00 AM10:45 PMClinical Review of Calcium Channel Blockers (CCBs)
10:45 AM11:15 PMClinical Review of Calcium Channel Blocker/ACE Inhibitor Combinations
11:15 PM12:15 PMLunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
12:15 PM12:30 PMFinal Recommendations for preferred drugs (CCBs and CCB/ACEl Combinations)
12:30 PM1:15 PMClinical Review of Beta Blockers
1:15 PM1:45 PMClinical Review of Bisphosphonates
1:45 PM2:30 PM Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
2:30 PM 2:45 PM Final Recommendations for preferred drugs (Beta Blockers and Bisphosphonates)
2:45 PM 2:55 PM Initial Report on the Prescription Proton Pump Inhibitor Prior Authorization Program
2:55 PM 3:00 PM Final Comments and Adjournment

*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.